{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:23:24Z","timestamp":1777764204766,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8227131503"],"award-info":[{"award-number":["8227131503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dmd.2026.100248","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:42:40Z","timestamp":1770104560000},"page":"100248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New strategy to quantify hepatic cytochrome P450 3A activity with deoxyschizandrin as an in vivo probe: A V approach"],"prefix":"10.1016","volume":"54","author":[{"given":"Xiaodong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.dmd.2026.100248_bib1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"10.1016\/j.dmd.2026.100248_bib2","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2146\/ajhp060080","article-title":"Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors","volume":"63","author":"Utecht","year":"2006","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"10.1016\/j.dmd.2026.100248_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ctrv.2011.12.003","article-title":"Phenotyping drug disposition in oncology","volume":"38","author":"Opdam","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.dmd.2026.100248_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-6147(99)01363-2","article-title":"Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment","volume":"20","author":"Ingelman-Sundberg","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.dmd.2026.100248_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100248_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bcp.2018.02.020","article-title":"Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics","volume":"153","author":"Ahmad","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2026.100248_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.711943","article-title":"CYP3A4\u221722 genotyping in clinical practice: ready for implementation?","volume":"12","author":"Mulder","year":"2021","journal-title":"Front Genet"},{"issue":"2\u20133","key":"10.1016\/j.dmd.2026.100248_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0167-4943(91)90024-K","article-title":"Aging of the liver: facts and theories","volume":"12","author":"Kitani","year":"1991","journal-title":"Arch Gerontol Geriatr"},{"issue":"11","key":"10.1016\/j.dmd.2026.100248_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00002512-200118110-00005","article-title":"Liver function and phase I drug metabolism in the elderly: a paradox","volume":"18","author":"Schmucker","year":"2001","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.dmd.2026.100248_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11095-006-0277-7","article-title":"CYP induction-mediated drug interactions: in vitro assessment and clinical implications","volume":"23","author":"Lin","year":"2006","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100248_bib12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/cpt.3347","article-title":"Aging-related CYP3A functional changes in Chinese older patients: new findings from model-based assessment of amlodipine","volume":"116","author":"Valerie Sia","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100248_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200847030-00005","article-title":"In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine","volume":"47","author":"Lobo","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2026.100248_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122658","article-title":"The determination of the Paraxanthine\/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS\/MS","volume":"234","author":"Lajin","year":"2021","journal-title":"Talanta"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2026.100248_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1081\/DMR-120001388","article-title":"Human CYPs: in vivo and clinical aspects","volume":"34","author":"Pelkonen","year":"2002","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.dmd.2026.100248_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","article-title":"Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes","volume":"10","author":"Streetman","year":"2000","journal-title":"Pharmacogenetics"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1067\/mcp.2001.115447","article-title":"CYP3A activity in European American and Japanese men using midazolam as an in vivo probe","volume":"69","author":"Tateishi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100248_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1067\/mcp.2003.29","article-title":"Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo","volume":"73","author":"Lowry","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100248_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5414\/CPP47111","article-title":"Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe","volume":"47","author":"Ma","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100248_bib20","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1124\/dmd.110.035295","article-title":"Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7","volume":"38","author":"Seo","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"6990","key":"10.1016\/j.dmd.2026.100248_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1124\/dmd.107.019539","article-title":"Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans","volume":"36","author":"Klieber","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100248_bib23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2026.100248_bib24","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","article-title":"Erythromycin","year":"2012"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/dmd.105.008607","article-title":"Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion","volume":"34","author":"Eriksson","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.2012.106","article-title":"OATP1B1 polymorphism as a determinant of erythromycin disposition","volume":"92","author":"Lancaster","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2026.100248_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","article-title":"In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration","volume":"11","author":"Lin","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clpt.2005.08.004","article-title":"Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam","volume":"78","author":"Chaobal","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100248_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/clpt.2013.27","article-title":"A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions","volume":"93","author":"Halama","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.dmd.2026.100248_bib30","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2174\/1389200224666221209154002","article-title":"Influence of Zhuanggu Guanjie Pill on seven cytochrome P450 enzymes based on probe cocktail and pharmacokinetics approaches","volume":"23","author":"Chai","year":"2022","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2026.100248_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jmgm.2014.11.013","article-title":"Structural basis for cooperative binding of azoles to CYP2E1 as interpreted through guided molecular dynamics simulations","volume":"56","author":"Levy","year":"2015","journal-title":"J Mol Graph Model"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/bj1350101","article-title":"Steady-state enzyme kinetics with high-affinity substrates or inhibitors. A statistical treatment of dose-response curves","volume":"135","author":"Henderson","year":"1973","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.113.053884","article-title":"Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A","volume":"42","author":"Wu","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100248_bib34","first-page":"3181","article-title":"Esophageal and hepatic microsomal metabolism of N-nitrosomethylbenzylamine and N-nitrosodimethylamine in the rat","volume":"42","author":"Labuc","year":"1982","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jpba.2005.10.031","article-title":"Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids","volume":"41","author":"Taylor","year":"2006","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.dmd.2026.100248_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.109.030254","article-title":"Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans","volume":"38","author":"Watanabe","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.xphs.2023.05.019","article-title":"A complete extension of classical hepatic clearance models using fractional distribution parameter FD in physiologically based pharmacokinetics","volume":"113","author":"Jeong","year":"2024","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1124\/dmd.107.019174","article-title":"Role of haptoglobin on the uptake of native and beta-chain [trimesoyl-(Lys82)beta-(Lys82)beta] cross-linked human hemoglobins in isolated perfused rat livers","volume":"36","author":"Chow","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100248_bib40","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3762\/bjnano.14.85","article-title":"Recognition mechanisms of hemoglobin particles by monocytes \u2013 CD163 may just be one","volume":"14","author":"Nimz","year":"2023","journal-title":"Beilstein J Nanotechnol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100248_bib41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF01062014","article-title":"Effects of perfusate flow rate on measured blood volume, Disse space, intracellular water space, and drug extraction in the perfused rat liver preparation: characterization by the multiple indicator dilution technique","volume":"16","author":"Pang","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"10.1016\/j.dmd.2026.100248_bib42","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0022-3565(24)29597-5","article-title":"Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process","volume":"297","author":"Hung","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100248_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol Ind Health"},{"issue":"6","key":"10.1016\/j.dmd.2026.100248_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","article-title":"Applications of minimal physiologically-based pharmacokinetic models","volume":"39","author":"Cao","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01062191","article-title":"Physiologic modeling of cyclosporin kinetics in rat and man","volume":"19","author":"Bernareggi","year":"1991","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib46","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.10128","article-title":"Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition","volume":"91","author":"Poulin","year":"2002","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.dmd.2026.100248_bib47","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1124\/dmd.119.087973","article-title":"Prediction of tissue-plasma partition coefficients using microsomal partitioning: incorporation into physiologically based pharmacokinetic models and steady-state volume of distribution predictions","volume":"47","author":"Holt","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100248_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/ph16111529","article-title":"Ethylmethylhydroxypyridine succinate is an inhibitor but not a substrate of ABCB1 and SLCO1B1","volume":"16","author":"Shchulkin","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"10.1016\/j.dmd.2026.100248_bib49","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD impairs nonrenal clearance of fexofenadine but not midazolam","volume":"20","author":"Nolin","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100248_bib50","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100248_bib51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/1389200211209050599","article-title":"Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes","volume":"13","author":"Wu","year":"2012","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.dmd.2026.100248_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-011-0077-2","article-title":"Stress can affect drug pharmacokinetics via serum\/tissues protein binding and blood flow rate alterations","volume":"37","author":"Antonia","year":"2012","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmd.2026.100248_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234835","article-title":"Plasma volume, cell volume, total blood volume and F factor in the tree shrew","volume":"15","author":"Xia","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.dmd.2026.100248_bib54","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1213\/ANE.0000000000005018","article-title":"Perioperative management of children on ketogenic dietary therapies","volume":"131","author":"Conover","year":"2020","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.dmd.2026.100248_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/ph17040473","article-title":"Pharmacokinetics, pharmacodynamics, and side effects of midazolam: a review and case example","volume":"17","author":"Peter","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.dmd.2026.100248_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.biopha.2018.11.069","article-title":"Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development","volume":"110","author":"Chen","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100248_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450\u2013mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100248_bib58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:59:29Z","timestamp":1777474769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0090955626000176"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100248","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New strategy to quantify hepatic cytochrome P450 3A activity with deoxyschizandrin as an in vivo probe: A Vmax, app approach","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100248"}}